Summer Street weighs in on the FDA's delay of Auxilium's PDUFA date for Xiaflex; advises caution

Summer Street weighs in on Auxilium's (AUXL +6.2%) announcement that the FDA extended its PDUFA date of the company's NDA for Xiaflex, saying they remain pessimistic on FDA approval and believe the agency won't approve the application without holding an advisory committee meeting.

The PDUFA date was extended 3 months to December 6th because a late submission of information was classified as a major amendment to the NDA.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs